Predicting survival in cancer patients: The role of cachexia and hormonal, nutritional and inflammatory markers

Journal of Cachexia, Sarcopenia and Muscle

Volumn 3, Issue 4, 2012, Pages 245-251

  Utech, Anne E ^a   Tadros, Eiriny M ^a   Hayes, Teresa G ^a   Garcia, Jose M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Anorexia; Inflammation; Interleukin 6; Testosterone; TNF

Indexed keywords

ALBUMIN; HEMOGLOBIN; HORMONE; INTERLEUKIN 6; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; APPETITE; ARTICLE; BIOAVAILABILITY; CACHEXIA; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; DISEASE MARKER; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NUTRITION; PREDICTIVE VALUE; PRIORITY JOURNAL; QUESTIONNAIRE; WEIGHT CHANGE;

EID: 84879206420     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1007/s13539-012-0075-5     Document Type: Article

References (35)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003;53: 5-26.
2. Maltoni M, Nanni O, Pirovano M, Scarpi E, Indelli M, Martini C, et al. Successful validation of the palliative prognostic score in terminally ill cancer patients. Italian multicenter study group on palliative care. J Pain Symptom Manage. 1999;17: 240-7.
3. Strasser F, Bruera ED. Update on anorexia and cachexia. Hematol Oncol Clin North Am. 2002;16: 589-617.
4. Sonti G, Ilyin SE, Plata-Salaman CR. Anorexia induced by cytokine interactions at pathophysiological concentrations. Am J Physiol. 1996;270: R1394-402.
5. Opara EI, Laviano A, Meguid MM. Correlation between food intake and cerebrospinal fluid interleukin 1 alpha in anorectic tumor-bearing rats. Nutrition. 1995;11: 678-9.
6. Laviano A, Gleason JR, Meguid MM, Yang ZJ, Cangiano C, Rossi Fanelli F. Effects of intra-VMN mianserin and IL-1ra on meal number in anorectic tumor-bearing rats. J Investig Med. 2000;48: 40-8.
7. Jatoi A, Daly BD, Hughes VA, Dallal GE, Kehayias J, Roubenoff R. Do patients with nonmetastatic non-small cell lung cancer demonstrate altered resting energy expenditure? Ann Thorac Surg. 2001;72: 348-51.
8. Vigano A, Bruera E, Jhangri GS, Newman SC, Fields AL, Suarez-Almazor ME. Clinical survival predictors in patients with advanced cancer. Arch Intern Med. 2000;160: 861-8.
9. Garcia JM, Garcia-Touza M, Hijazi RA, Taffet G, Epner D, Mann D, et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab. 2005;90: 2920-6.
10. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer. 2002;2: 862-71.
11. Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace Jr D, Corey E. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer. 2003;97: 1211-6.
12. Lee BN, Dantzer R, Langley KE, Bennett GJ, Dougherty PM, Dunn AJ, et al. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation. 2004;11: 279-92.
13. Lyngso D, Simonsen L, Bulow J. Metabolic effects of interleukin-6 in human splanchnic and adipose tissue. J Physiol. 2002;543: 379-86.
14. Homsi J, Luong D. Symptoms and survival in patients with advanced disease. J Palliat Med. 2007;10: 904-9.
15. Laviano A, Meguid MM. Nutritional issues in cancer management. Nutrition. 1996;12: 358-71.
16. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27: 793-9.
17. Garcia JM, Li H, Mann D, Epner D, Hayes TG, Marcelli M, et al. Hypogonadism in male patients with cancer. Cancer. 2006;106: 2583-91.
18. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991;7: 6-9.
19. Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Cancer. 2000;88: 2164-71.
20. Heedman PA, Strang P. Symptom assessment in advanced palliative home care for cancer patients using the ESAS: clinical aspects. Anticancer Res. 2001;21: 4077-82.
21. Genealogy Inc. Death master file [database on the Internet]. 2005. http://www. segenealogy. com/_search/vital_ssdi. htm. Accessed 7 Aug 2010.
22. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980;69: 491-7.
23. Reuben DB, Mor V, Hiris J. Clinical symptoms and length of survival in patients with terminal cancer. Arch Intern Med. 1988;148: 1586-91.
24. Vigano A, Donaldson N, Higginson IJ, Bruera E, Mahmud S, Suarez-Almazor M. Quality of life and survival prediction in terminal cancer patients: a multicenter study. Cancer. 2004;101: 1090-8.
25. Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, Kaur G, Bruera E. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer. 2004;100: 851-8.
26. Fouladiun M, Korner U, Bosaeus I, Daneryd P, Hyltander A, Lundholm KG. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care-correlations with food intake, metabolism, exercise capacity, and hormones. Cancer. 2005;103: 2189-98.
27. Simons JP, Schols AM, Buurman WA, Wouters EF. Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. Clin Sci (Lond). 1999;97: 215-23.
28. Tas F, Duranyildiz D, Argon A, Oguz H, Camlica H, Yasasever V, et al. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med Oncol. 2005;22: 353-8.
29. Dulger H, Alici S, Sekeroglu MR, Erkog R, Ozbek H, Noyan T, et al. Serum levels of leptin and proinflammatory cytokines in patients with gastrointestinal cancer. Int J Clin Pract. 2004;58: 545-9.
30. Yeh SS, Hafner A, Chang CK, Levine DM, Parker TS, Schuster MW. Risk factors relating blood markers of inflammation and nutritional status to survival in cachectic geriatric patients in a randomized clinical trial. J Am Geriatr Soc. 2004;52: 1708-12.
31. Levine JA, Morgan MY. Preservation of macronutrient preferences in cancer anorexia. Br J Cancer. 1998;78: 579-81.
32. Strasser F, Palmer JL, Schover LR, Yusuf SW, Pisters K, Vassilopoulou-Sellin R, et al. The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study. Cancer. 2006;107: 2949-57.
33. Del Fabbro E, Hui D, Nooruddin ZI, Dalal S, Dev R, Freer G, et al. Associations among hypogonadism, C-reactive protein, symptom burden, and survival in male cancer patients with cachexia: a preliminary report. J Pain Symptom Manage. 2010;39: 1016-24.
34. Taira AV, Merrick GS, Galbreath RW, Butler WM, Wallner KE, Allen ZA, et al. Pretreatment serum testosterone and androgen deprivation: effect on disease recurrence and overall survival in prostate cancer patients treated with brachytherapy. Int J Radiat Oncol Biol Phys. 2009;74: 1143-9.
35. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle. 2010;1: 7-8.